Piper Sandler raised the firm’s price target on Omega Therapeutics to $10 from $8 and keeps an Overweight rating on the shares. The analyst factored in the financing and rolled forward the firm’s discount period to the end of 2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on OMGA:
- Omega Therapeutics reports Q4 EPS (64c), consensus (63c)
- Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Omega Therapeutics chairman Afeyan buys $19.2M in common stock
- Omega Therapeutics announces $40M registered direct offering
- Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock